Lavipharm SA operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lavipharm SA with three other
pharmaceutical manufacturers in Europe:
Moberg Pharma AB (publ)
sales of 334.30 million Swedish Kronor [US$39.48 million]
of which 45%
was Kerasal Nail /Nalox),
Horizon Discovery Group PLC
of the United Kingdom
(£24.07 million [US$32.31 million]
of which 53%
was Services), and
based in the United Kingdom
(£19.85 million [US$26.64 million]
of which 100%
was Medical and Scientific Research).
Lavipharm SA reported sales of 31.14 million Euro (US$36.63 million)
December of 2016.
increase of 18.1%
versus 2015, when the company's sales were 26.37 million Euro.